Novel use of rituximab for steroid-dependent nephrotic syndrome in children

American Journal of Nephrology

Volumn 38, Issue 6, 2014, Pages 483-488

  Kimata, Takahisa ^a   Hasui, Masafumi ^a   Kino, Jiro ^a   Kitao, Tetsuya ^a   Yamanouchi, Sohsaku ^a   Tsuji, Shoji ^a   Kaneko, Kazunari ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Children; Minimal change disease; Rituximab; Steroid dependent nephrotic syndrome

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; CYCLOSPORIN B; MYCOPHENOLATE MOFETIL;

ADOLESCENT; ARTICLE; CATARACT; CHILD; CLINICAL ARTICLE; CLINICAL INDICATOR; DRUG DEPENDENCE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPERTENSION; MALE; NEPHROTIC SYNDROME; OBESITY; OSTEOPOROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPIRATORY DISTRESS; SCHOOL CHILD; SHORT STATURE; STEROID DEPENDENT NEPHROTIC SYNDROME; STEROID THERAPY; UNSPECIFIED SIDE EFFECT; CHILDHOOD DISEASE; DISEASE COURSE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; REPEATED DRUG DOSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; RECURRENCE; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 84893077911     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000356439     Document Type: Article

References (39)

1. Kaneko K: Pathogenesis in childhood idio-pathic nephrotic syndrome: an update of patchwork. Curr Pediatr Rev 2009; 5: 55-64.
2. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y: Independent risk factors for chronic cyclosporine-induced ne-phropathy in children with nephrotic syndrome. Arch Dis Child 2006; 91: 666-670. (Pubitemid 44197108)
3. Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF: Cyclosporine-A-induced nephro-toxicity in children with minimal-change ne-phrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 2008; 23: 581-586.
4. Latta K, von Schnakenburg C, Ehrich JH: A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16: 271-282. (Pubitemid 32229852)
5. Benz K, Dötsch J, Rascher W, Stachel D: Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19: 794-797. (Pubitemid 38931165)
6. Gilbert RD, Hulse E, Rigden S: Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006; 21: 1698-1700. (Pubitemid 44390835)
7. François H, Daugas E, Bensman A, Ronco P: Unexpected efficacy of rituximab in multire-lapsing minimal change nephrotic syndrome in the adult: first case report and pathophysi-ological considerations. Am J Kidney Dis 2007; 49: 158-161. (Pubitemid 44932200)
8. Smith GC: Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 2007; 22: 893-898. (Pubitemid 46629628)
9. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosen-thal K, Rosahl A, Mueller-Wiefel DE, Dötsch J: Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915.
10. Dallachio IA, Trimoreau F, Feuillard J, Gui-goinis V: A case of steroid-dependent ne-phrotic syndrome treated with rituximab (abstract). Pediatr Nephrol 2006; 21: 1615.
11. Hofstra JM, Deegens JK, Wetzels JF: Ritux-imab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 2007; 22: 2100-2102. (Pubitemid 47244800)
12. Guigonis V, Dallocchio A, Baudouin V, De-hennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F: Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pedi-atr Nephrol 2008; 23: 269-279.
13. Bagga A, Sinha A, Moudgil A: Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752. (Pubitemid 47001064)
14. Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K: Rituximab for refractory focal segmental glomerulosclero-sis. Pediatr Nephrol 2008; 23: 481-485.
15. Yang T, Nast CC, Vo A, Jordan SC: Rapid remission of steroid and mycophenolate mofetil-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 2008; 23: 377-380. (Pubitemid 351767391)
16. Suri M, Tran K, Sharma AP, Filler G, Grimmer J: Remission of steroid-resistant nephrot-ic syndrome due to focal and segmental glo-merulosclerosis using rituximab. Int Urol Nephrol 2008; 40: 807-810.
17. Kamei K, Ito S, Nozu K, Fujinaga S, Nakaya-ma M, Sako M, Saito M, Yoneko M, Iijima K: Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24: 1321-1328
18. ISKDC: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561-564.
19. Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA: Management of childhood-onset nephrot-ic syndrome. Pediatrics 2009; 124: 747-757.
20. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lympho-cytic lymphoma. J Clin Oncol 2000; 18: 317-324. (Pubitemid 30056420)
21. Armitage JD, Montero C, Benner A, Armitage JO, Bociek G: Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma 2008; 8: 253-255.
22. Poterucha JT, Westberg M, Nerheim P, Lovell JP: Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J 2010; 37: 218-220.
23. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T: A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81: 169-170. (Pubitemid 40270992)
24. Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM, Avivi I: The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfa- methoxazole: a single-center experience. Acta Haematol 2012; 127: 110-114.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2 (suppl):139-274.
26. Shalhoub RJ: Pathogenesis of lipoid nephro-sis: a disorder of T-cell function. Lancet 1974; 2: 556-560.
27. Grimbert P, Audard V, Remy P, Lang P, Sa-hali D: Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2003; 18: 245-248. (Pubitemid 36181671)
28. Kemper MJ, Meyer-Jark T, Lilova M, Müller-Wiefel DE: Combined T-and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 2003; 60: 242-247. (Pubitemid 37258847)
29. Iharada A, Kaneko K, Tsuji S, Hasui M, Kan-da S, Nishiyama T: Increased nitric oxide production by T and B cells in idiopathic ne-phrotic syndrome. Pediatr Nephrol 2009; 24: 1033-1038.
30. Sellier-Leclerc AL, Macher MA, Loirat C, Guerin V, Watier H, Peuchmaur M, Baudouin V, Deschenes G: Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25: 1109-1115.
31. Haffner D, Fischer DC: Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24: 1433-1438.
32. Chan AC: Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci Transl Med 2011; 85: 85ps21.
33. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclero-sis. Sci Transl Med 2011; 85: 85ra46.
34. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M: Fatal Pneumocystis pneumonia following rituxi-mab administration for rheumatoid arthri-tis. Rheumatology 2008; 47: 1256-1257. (Pubitemid 352038242)
35. Kumar D, Gourishankar S, Mueller T, Cock-field S, Weinkauf J, Vethanayagam D, Humar A: Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11: 167-170.
36. Shelton E, Yong M, Cohney S: Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009; 14: 96-99.
37. Alexandrescu DT, Dutcher JP, O'Boyle K, Al-bulak M, Oiseth S, Wiernik PH: Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 2321-2325. (Pubitemid 39504329)
38. Chaumais MC, Garnier A, Chalard F, Peuch-maur M, Dauger S, Jacqz-Agrain E, Des-chênes G: Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24: 1753-1755.
39. Delbe-Bertin L, Aoun B, Tudorache E, Lapil-lone H, Ulinski T: Does rituximab induce hy-pogammaglobulinemia in patients with pedi-atric idiopathic nephrotic syndrome? Pediatr Nephrol 2013; 28: 447-451.